Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients develop sunitinib resistance and progressive disease after about 1 year of treatment. In this study, we evaluated t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Huang, Dan, Ding, Yan, Zhou, Ming, Rini, Brian I., Petillo, David, Qian, Chao-Nan, Kahnoski, Richard, Futreal, P. Andrew, Furge, Kyle A., Teh, Bin Tean
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3719378/
https://ncbi.nlm.nih.gov/pubmed/20103651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3965
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia